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Abstract 
Purpose: In patients with Addison’s disease (AD), a dual-release preparation of hydrocortisone (Plenadren, PLEN) 
has been demonstrated to maintain cortisol levels in a more physiological range than conventional glucocorticoid 
therapy, and to exert positive effects. This study aimed to assess variations of anthropometric, metabolic and hormonal 
parameters in patients with AD after switching from conventional hydrocortisone (HC) treatment to PLEN.  
Methods: in nineteen AD patients (15 F and 4 M, age 27-65 yr) treated with HC 20 mg/day thrice daily, body weight, 
BMI, waist circumference, fasting glucose, HbA1c, serum lipids, plasma renin activity (PRA), electrolytes and blood 
pressure were evaluated at baseline, and 1, 3, 6 and 12 months after switching from HC to PLEN. At baseline, and 
after 1 and 12 months of PLEN, blood ACTH and cortisol (at 0800 h at fasting, and 30, 60, 90, 120 and 240 minutes 
after drug ingestion), and health-related quality of life (HRQoL), using 30-AddiQoL questionnaire, were evaluated.  
Results: During PLEN, waist and serum lipid progressively decreased. After 12 months of PLEN, a significant 
difference was observed in waist circumference (P=0.007), HbA1c (P=0.002), total and LDL-cholesterol levels 
(P<0.05). ACTH levels at 240 minutes and the area under the curve (AUC) were lower (P<0.05) during PLEN than 
HC, while cortisol peaks and AUC were similar. 30-AddiQoL total score also improved (P=0.04) during PLEN.  
Conclusions: In Addison’s disease patients, PLEN reduces central adiposity, and improves glucose and metabolism 
parameters and HRQoL. 
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Introduction 
In patients with Addison’s disease (AD) glucocorticoids (GC) are insufficiently secreted, so that replacement therapy 
is essential for health and, indeed, life [1-5].  
Primary aim of GC replacement therapy is to reproduce the physiological circadian pattern of cortisol secretion by the 
normal adrenal gland as much as possible. At the same time, the pharmacokinetic of available oral fast-release GC, 
hydrocortisone or cortisone, makes impossible to fully mimic physiological cortisol secretion rhythm [4 ,6].  
Moreover, despite GC replacement therapy patients with adrenal insufficiency present higher mortality rates, typically 
from cardiovascular diseases, and increased morbidity, mainly obesity and glycometabolic alterations, as compared to 
the general population [7-13]. Likely explanations are supra-physiological GC maintenance doses [14], poor diurnal 
GC exposure-time profile [15], and inadequate rescue therapy in response to intercurrent illnesses [16,17]. Finally, 
patients with AD also present impaired health-related quality of life (HRQoL) [18-20]. 
A dual-release preparation of hydrocortisone (PLENADREN; PLEN; ViroPharma, Maidenhead, UK) was developed 
to maintain cortisol levels in a more physiological range [21]. A Swedish multicenter study conducted in AD, has 
demonstrated that, compared to conventional GC treatment with hydrocortisone, PLEN reduces body weight and 
blood pressure, and improves glucose metabolism and HRQoL [22]. 
Based on these premises, we designed a clinical prospective study aimed at evaluating the anthropometric,  metabolic 
and hormonal profile, as well as HRQoL in a group of patients with AD, under conventional hydrocortisone treatment 
and after 1, 3, 6 and 12 months of PLEN. 
 
Subjects and Methods 
Subjects 
Nineteen patients with autoimmune Addison’s disease (F:M=15:4; mean age 47.3 ± 3.2 yr, range 27-65) were 
enrolled. Ten patients had normal weight, 7 were overweight (BMI 25-30 kg/m
2
) and 2 were obese (BMI>30 kg/m
2
). 
Two patients presented with isolated autoimmune AD, 17 were affected by autoimmune-poliendocrine syndrome 
(APS), 14 of type 2 (APS 2), 2 of  type 1 (APS 1), and 1 of  type 4 (APS 4). 
The diagnosis of autoimmune Addison’s disease was based on the presence of circulating adrenal autoantibodies 
against the steroidogenetic enzyme 21-hydroxylase (21OHAb), determined in radio binding assay that uses in vitro 
translated recombinant human 35S-21OH, and expressing 21OHAb levels as a relative index (21OH index) based on 
the analysis of one positive and two negative standard sera included in each assay, with the upper level of normal for 
the 21OH index that was 0.06 [23].  
Exclusion criteria were clinical or laboratory signs of severe cerebral, cardiovascular, respiratory, hepatobiliary or 
pancreatic disease; renal dysfunction; gastrointestinal emptying or motility disturbances, and immunosuppressive 
steroid therapy.  
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All pre-menopausal women were studied in the early follicular phase; the two patients with primary ovary 
insufficiency (case 6 and 11) were under appropriate hormonal replacement therapy (HRT) at the time of the study, 
and were evaluated in the estrogen phase (days 5–10 of HRT). 
Patients with autoimmune hypothyroidism were under appropriate treatment with l-thyroxin at the time of the study. 
At baseline evaluation, all the patients had been treated with hydrocortisone (HC, 20 mg/day, thrice/daily), and 
fludrocortisone (0.025-0.1 mg/day, once/daily), for at least 6 months. They were then switched to a dual-release 
hydrocortisone (PLEN, 20 mg/day), administered orally in the morning at fasting. All patients were instructed to add a 
rescue dose of HC during an intercurrent illness or stress (5 or 10 mg dose according to severity of stress and 
symptoms). 
None of the patients was affected by arterial hypertension, whereas 3 of them were affected by type 1 (case 8, 9 and 
11) or type 2 (case 7) diabetes mellitus. 
The main clinical patients features at baseline are reported in Table 1. 
All patients gave their written informed consent to participate in the study, which had been approved by the Ethical 
Committee of the University of Turin, in agreement with the principles of the Declaration of Helsinki. 
The patients were recruited among patients affected by autoimmune Addison’s disease, consecutively evaluated at the 
Division of Endocrinology, Diabetes and Metabolism, fitting specific inclusion criteria, and that agreed to switch from 
conventional hydrocortisone therapy to Plenadren. 
The study was conducted between September 2012 and September 2014. 
 
Evaluation of clinical parameters and health-related quality of life 
Body weight, body mass index (BMI), waist circumference and blood pressure were measured using standard methods 
at baseline, and after 1, 3, 6 and 12 months of treatment with PLEN. 
Health-related quality of life (HRQoL) was evaluated by a new 30-item questionnaire (AddiQoL), purposely 
developed and validated in patients with Addison’s disease [24, 25], administered in the morning. The algebraic sum 
of the various items scores was calculated: a higher score indicated a better HRQoL. 
 
Biochemical evaluation 
Blood samples were collected from all patients at fasting, between 0800 and 0900 h, before and after 30,60, 90, 120 
and 240 minutes after drug ingestion, and at least 30 minutes after venous cannulation kept patent by slow infusion of 
isotonic saline. 
Blood fasting glucose, HbA1C, total cholesterol, total and high density lipoprotein (HDL) cholesterol, triglycerides, 
sodium (Na), potassium (K), ACTH, cortisol (F) and plasma renin activity (PRA) levels were directly measured, while 
low density lipoprotein (LDL) cholesterol was calculated by Friedewald equation.  
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Serum glucose levels (mg/dl; 1 mg/dl=18 mmol/l) were measured by enzymatic method based on hexokynase reaction, 
traceable according to isotope dilution/mass spectrometry (ID/MS) standards.  
Serum total cholesterol (mg/dl; 1 mg/dl=38.6 mmol/l), and triglycerides (mg/dl; 1 mg/dl=88.5 mmol/l) levels were 
measured by enzymatic colorimetric assay, standardized according to ID/MS standards. 
Serum HDL cholesterol levels (mg/dl; 1 mg/dl=38.6 mmol/l) were measured by enzymatic colorimetric homogeneous 
test (immunoseparation followed by enzymatic cholesterol assay), standardized according to the US national reference 
system for cholesterol measurement, Cholesterol Reference Method Laboratory Network – CRMLN.  
HbA1C levels (mmol/mol) were measured by gold standard ion-exchange high-performance liquid chromatography 
(HPLC, Tosoh Bioscience, Inc., San Francisco, CA, USA).  
Serum Na and K were measured using ion-selective electrode system (Cobas ISE module), fully automated on routine 
clinical biochemistry analyzers. 
All the above mentioned analysis were performed on Roche/Hitachi Cobas c automated platforms (Roche 
Diagnostics), being coefficient of variations <1.9% for both within-run and between-run evaluations.             
Serum cortisol (F) levels (µg/dl; 1 µg/dl=27.59 mmol/l) were measured by automated immunoassay on Cobas e601 
instrument (Roche Diagnostics GmbH, Mannheim, Germany) based on a competitive electrochemiluminescence 
immunoassay, with an analytical sensitivity of 0.018 µg/dl, and intra- and inter-assay precision ranging from 3.0% to 
5.7%, and from 2.4% to 6.2%, respectively. 
Plasma ACTH levels (pg/ml; 1 pg/ml=4.5 pmol/l) were measured by solid-phase, two-site sequential 
chemiluminescent immunometric assay (Immulite 2000, Siemens Healthcare Diagnostics Inc., USA), with an 
analytical sensitivity of 5 pg/ml, and intra- and inter-assay precision ranging from 6.7 to 9.5%, and from 6.1% to 
10.0%, respectively. 
Plasma Renin Activity (PRA; ng/ml/h; 1 ng/ml/h=3.6 ng/(l*s)) levels were measured by radioimmunoassay of 
angiotensin I (Beckman Coulter), after its generation in plasma samples as the result of the enzymatic cleavage of the 
renin substrate, angioteninogen, in the presence of ACE inhibitor, by radioimmunological competition assay, using 
anti-angiotensin I polyclonal antibody-coated tubes. Analytical and functional sensitivity were 0.07 ng/ml/h and 0.20 
ng/ml/h, respectively, with an intra- and inter-assay variation coefficient ranging from 11.3 to 20.9%, respectively. 
 
Statistical analysis 
Results are expressed as median and range.  
The various parameters were compared by non-parametric Wilcoxon matched-pairs signed-rank test, using Statistical 
Package for the Social Science (IBM SPSS 21.0 for Windows).  
A P value <0.05 was considered significant. 
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Results 
During PLEN treatment, body weight, BMI and waist circumference progressively decreased, although as compared to 
baseline during HC, a significant reduction (P=0.007) was observed only for waist circumference after 12 months of 
PLEN treatment (median/range, 12 months vs. baseline: 78.0/60.0-103.0 vs. 82.0/65.0-110.0 cm), with no differences 
between normal-weight and overweight/obese patients (data not shown). (Fig. 1)  
No significant differences of fasting glucose or HbA1c levels were detected up to 6 month treatment, while HbA1c 
levels significantly decreased at 12 months in the whole group of patients (42.0/23-61 vs. 44.0/24-74 mmol/mol; 
P=0.002; Fig. 2) and in the subgroup of 15 non-diabetic patients (40.0/23-46 vs. 42.0/24-49 mmol/mol; P=0.004; data 
not shown). Considering the subgroup of 4 diabetic patients, HbA1C showed a progressive reduction since the sixth 
month of treatment in all cases (Table 2), with a consequent reduction of insulin requirement in type 1 diabetic 
patients (data not shown). 
A progressive decrease of total (baseline vs. 1, 3, 6 and 12 months: 208/145-271 vs. 182/128-272, 180/149-273, 
178/139-234 and 172/120-229 mg/dl; P<0.05 vs. baseline from time 3 months) and LDL cholesterol levels 
(107.4/59.6-173.6 vs. 95.8/45-165.6, 67.2/65-162.2, 89/51-164.4 and 85.6/51.4-152.0 mg/dl; P<0.05 vs. baseline from 
time 1 month) was observed during PLEN treatment; on the contrary, triglycerides and HDL cholesterol levels did not 
significantly change (Fig. 3). 
PLEN induced a decrease in ACTH levels more marked than HC, being ACTH levels at 240 minutes after drug 
ingestion and AUC curve lower during PLEN than HC (P<0.05), despite similar F peaks and AUC. (Table 3, Fig. 4) 
No significant changes in PRA, blood pressure and electrolytes were observed during PLEN treatment (data not 
shown). 
The total AddiQoL total score increased during PLEN treatment, with a reported significant improvement of QoL at 
12 months (P=0.04). Interestingly, fatigue scores increased, although not significantly (P=0.052), while scores for the 
other item categories were similar at baseline during HC and after PLEN treatment (Table 4). 
The most commonly reported adverse events were fatigue (5 out of 19 patients) and influenza (2 out of 19 patients), 
both occurring in the first 3 months of treatment. No severe adverse event was reported. 
The reported number of days during PLEN in which patients had to increase HC dosage for intercurrent illnesses or 
physical stresses was similar to that reported during previous conventional HC. 
 
Discussion  
Our data clearly showed that in patients with Addison’s disease, the switch from conventional hydrocortisone 
replacement treatment to dual-release hydrocortisone replacement therapy is associated with a significant reduction in 
central adiposity, together with an improvement of glucose and lipid metabolism and HRQoL. 
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Studies performed in 1960s suggested a normalization of life expectancy and quality in patients with Addison's disease 
during appropriate replacement treatment [26]. Afterwards, it has become increasingly clear that, on the contrary, 
despite glucocorticoid replacement therapy, mortality rate and morbidity remain increased in patients with adrenal 
insufficiency as compared to the general population [7-10]. 
In particular, there is a more than a two-fold increase in relative risk of death in Swedish patients with AD, 
predominantly due to cardiovascular, malignant, and infectious diseases [7,8]. The same for Norwegian patients with 
AD, particularly males, presenting with an increased risk of premature death due to infections, sudden death and acute 
adrenal failure [9].  
Moreover, a higher prevalence of central adiposity, impaired glucose tolerance and dyslipidemia, recognized as 
independent risk factors for cardiovascular disease, have been demonstrated in several studies during treatment [10-
13]. 
A recent cross-sectional study performed by Ross et al. [10] in the population of South Africa demonstrated an 
increase in cardiovascular risk factors, especially dyslipidemia, in AD patients as compared to healthy controls 
matched by age, gender, ethnicity and BMI. A second study from the same group [11] compared cardiovascular risk 
factors in AD patients from South Africa and from Sweden, demonstrating a significant presence of hypertension and 
diabetes in both groups, but a worse lipid profile and higher levels of inflammation markers in the first group, despite 
the lower replacement doses of hydrocortisone. Overall, these results support the hypothesis of AD as an independent 
risk factor for cardiovascular disorders, although the overall cardiovascular risk derives from the association of AD 
and several other environmental and genetic factors. 
Since the conventional glucocorticoid replacement therapy often exceed the normal endogenous cortisol production 
rate, it could be expected that using supra-physiological doses of glucocorticoids may increase the prevalence of risks 
for cardiovascular diseases. Indeed, traditional synthetic glucocorticoids did not fully mimic physiological circadian 
cortisol rhythm, as serum cortisol levels were abundantly above the expected physiological levels right after tablet 
intake, with a rapid decrease in the following hours, often reaching undetectable levels [4, 15]. 
Based on these premises, a number of studies have explored different hydrocortisone formulations trying to identify 
the best doses and patterns of replacement treatment.  
In particular, a dual-release preparation of hydrocortisone (Plenadren) was developed to maintain cortisol levels in a 
more physiological range, as clearly demonstrated in a phase I study [21].  
To date, a single phase II multicenter study has assessed the effect of Plenadren on metabolic parameters and HRQoL 
in patients with AD. This study, performed in 64 Swedish patients with AD, demonstrated that, compared to 
conventional HC, Plenadren significantly reduced body weight and blood pressure, and improve glucose metabolism 
and HRQoL after 12-week treatment [22]. 
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In agreement with Johannsson’s group [22], we found a remarkable improvement in glucose metabolism. Indeed, 
Plenadren was associated with an important, and early (in the subgroup of diabetic patients) reduction of HbA1c 
levels, while fasting glycemia was similar before and after treatment. Interestingly type 1 diabetes mellitus patients 
have reduced their insulin requirement during Plenadren treatment. 
Conventional replacement therapy results in large fluctuations of daily cortisol levels, directly influencing glucose 
homeostasis, which makes insulin treatment difficult to manage in diabetic patient. Specifically, increased evening 
exposure to cortisol has been shown to reduce glucose tolerance, insulin secretion and insulin sensitivity in healthy 
subjects [27]. In addiction, an increased insulin requirement, together with a higher frequency of severe hypoglycemia 
episodes have been reported in patients with type 1 diabetes associated to AD, as compared with patients with type 1 
diabetes only [28]. 
Differently from a previous study [22], although a trend towards weight reduction was observed in our patient, mean 
weight at 12 month follow-up was not significantly reduced from baseline. The lower mean weight and BMI in our 
patients at baseline could explain, at least partially, this difference. 
Interestingly, we firstly reported a significant reduction in waist circumference after 12 months of Plenadren treatment, 
that was independent from BMI. The absence of a body composition study could represent a minor study limitation as 
it would have helped in better characterizing differences in fat distribution, before and after treatment. 
With regards to lipid profile, we demonstrated a positive effect of Plenadren on levels of total and LDL cholesterol, 
not detected in the Swedish study [22]. 
Glucocorticoids have complex, still not fully elucidated effects on lipid metabolism, including direct and indirect 
actions on lipolysis, free fatty acid production and turnover, very-low density lipoproteins synthesis and fatty 
accumulation in liver [29]. Our data are supported by previous studies performed in patients with secondary 
hypoadrenalism, suggesting that long-term glucocorticoid replacement therapy can cause dyslipidemia, with a clear 
relation between glucocorticoid dose and levels of total cholesterol and LDL-cholesterol [14, 30]. Differently from 
previous observations that found a positive correlation between hydrocortisone dose and HDL-cholesterol [10], we did 
not find any modification on HDL-cholesterol levels during PLEN. 
As central adiposity, together with impaired glycolipid metabolism, are well recognized risk factors of cardiovascular 
diseases, our results suggest that patients treated with Plenadren have a safer cardiovascular profile with respect to 
conventional HC treatment. 
Considering that the total dose of Plenadren and HC administered in our study is similar, our results suggest that a 
more physiological daily cortisol profile is associated with an improvement of waist anthropometric and metabolic 
parameters. The reduction in 24-hoor hydrocortisone exposure with Plenadren may explain the reduction in waist, 
HbA1c and lipid parameters. 
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Although we did not perform complete daily serum cortisol curves, lower ACTH levels at 240 minutes after Plenadren 
ingestion, as compared to HC, suggest a more physiologic serum cortisol levels during the day. Plasma ACTH 
concentrations have not been usually considered for the definition of the adequacy of glucocorticoid replacement 
therapy. More recently, it has been suggested that ACTH profiles could be useful to assess the variable sensitivity to 
glucocorticoid activity in patients with Addison’s disease [29] and, therefore, should be used as additional parameter 
for the monitoring of glucocorticoid replacement [30]. The evaluation of 24-hours urinary free cortisol or salivary 
cortisol could add further information on cortisol exposure during the day. 
Differently from the Sweedish study [22], we did not observe a reduction of arterial pressure associated with 
Plenadren treatment. This could be do to the fact that none of our patient was hypertensive at enrollment. 
Finally, we confirmed the previously reported improvement in quality of life associated with Plenadren, with special 
regards to reduction, of fatigue, although not significant (this could be due to the low numbers of patients enrolled, so 
that longitudinal studies in larger cohorts of patients could clarify this aspect). 
A similar prevalence of minor adverse events was recorded between HC and Plenadren, being fatigue and influenza 
the most common, especially in the first month of treatment. We suppose this phenomenon could be related more to an 
increased awareness of associated signs and symptoms, than to a real change in cortisol regimen. At the same time, 
changes in cortisol exposure time can not be ruled out. 
Our study present some limitations. First, patients were not blinded to the treatment; therefore, their 
expectations on the efficacy of the new drug could have, at least partially, affected results. Secondly, the small number 
of patients, due to rarity of the disease, as well as the predominance of women, increases the risk of type 2 error and do 
not allow definitive conclusions. A case-controlled study, performed in a larger patient cohort and with a longer 
follow-up is mandatory in order to verify and explain these preliminary observations. 
Despite these limitations, the strength of our study is that is the first Italian study assessing anthropometric, 
metabolic and quality of life in a homogeneous cohort of patients with autoimmune Addison’s disease enrolled in a 
single tertiary care Italian center, after a relatively long (1 year)-period of treatment with Plenadren. 
In conclusion, our study provides further evidence that dual-release hydrocortisone preparation is efficacious in 
reducing central adiposity, improving glucose and lipids metabolism, as well as quality of life, in patients with 
Addison’s disease.
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Table 1. Clinical data of patients with Addison’s disease 
Case Gender Age Etiology Associated diseases Disease duration 
(n)  (yr)    (yr) 
1 F 58 APS2 BD, CAG 2 
2 M 39 APS2 HYPOTH 29 
3 F 49 APS2 HYPOTH 10 
4 M 54 APS2 HYPOTH 4 
5 F 62 APS2 HYPOTH, CAG 16 
6 F 27 APS1 AL, POI, HYPOPTH 10 
7 F 61 APS2 HYPOTH, CAG, DMT2 11 
8 F 29 APS2 HYPOTH, CAG, DMT1 7 
9 M 20 APS1 HYPOPTH, DMT1 11 
10 F 49 APS2 HYPOTH 3 
11 F 45 APS2 HYPOTH, POI, DMT1 6 
12 F 50 APS2 HYPOTH 7 
13 F 57 APS2 HYPOTH 33 
14 F 59 APS2 HYPOTH, CAG 7 
15 F 59 APS2 HYPOTH 42 
16 M 29 AI  11 
17 M 56 APS4 CAG, VIT 18 
18 F 65 AI  4 
19 F 30 APS2 HYPOTH 23 
 
AI: autoimmune isolated; APS: autoimmune polyendocrine syndrome type 1 (APS 1), type 2 (APS 2) or type 4 (APS 
4); AL: Alopecia; BD: Basedow’s disease; CAG: chronic atrophic gastritis; DMT1: diabetes mellitus type 1; DMT2: 
diabetes mellitus type 2; HYPOPTH: hypoparathyroidism; HYPOTH: hypothyroidism; VIT: vitiligo; POI: primary 
ovary insufficiency.
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Table 2. HbA1c (mmol/l) levels in 4 patients with Addison’s disease and diabetes mellitus 
Case HC PLEN 1M PLEN 3M PLEN 6M PLEN 12M 
(n)      
7 55.0 57.0 57.0 55.0 47.0 
8 58.0 62.0 68.0 53.0 53.0 
9 74.0 65.0 65.0 64.0 61.0 
11 62.0 57.0 59.0 58.0 56.0 
median 60.0 59.5 62.0 57.0 55.0 
lower 55.0 57.0 57.0 53.0 47.0 
upper 74.0 65.0 68.0 64.0 61.0 
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Table 3. (Median/range) ACTH levels (at 240 minutes after drug ingestions), cortisol (F) levels (peaks after drug 
ingestions), ACTH and F AUCs in patients with Addison’s disease during conventional hydrocortisone treatment 
(HC), and after 1 (1M) and 12 (12M) months of Plenadren (PLEN) 
 HC PLEN 1 M PLEN 12 M 
ACTH levels (pg/ml) 
ACTH AUC (pg/ml/h) 
140.0/170.0-600.0 
32110.0/18170.0-194746.0 
24.0*/5.0-298.0 
28307.0*/1072.0-151448.0 
26.0*/5.0-306.0 
23322.0*/1844.0-115615.0 
F levels (µg/dl) 
F AUC (µg/dl/h) 
25.0/13.2-33.3 
4092.1/2246.4-5428.3 
21.4/10.4-32.8 
4149.3/2423.1-6521.4 
19.0/10.5-26.8 
3915.3/2487.6-6400.6 
 
*P< 0.05 vs. HC 
  16 
Table 4. (Median/range) AddiQoL scores in patients with Addison’s disease during conventional hydrocortisone 
treatment (HC), and after 3 (3M) and 12 (12M) months of Plenadren (PLEN) 
AddiQoL Fatigue Emotions Symptoms Miscellaneous Total 
HC 20.0/18.0-27.0 21.0/17.0-28.0 23.0/19.0-32.0 12.0/6.0-18.0 76.0/68.0-100.0 
PLEN 3M 21.0/16.0-28.0 20.0/18.0-30.0 24.0/20.0-30.0 13.0/7.0-18.0 77.0/67.0-102.0 
PLEN 12M 22.0/17.0-28.0 21.0/17.0-30.0 24.0/20.0-29.0 13.0/10.0-18.0 80.0/70-104.0* 
 
*P= 0.04 vs. HC 
Fatigue: questions 1-5, 23, 26 and 27 
Emotions: questions 11-15, 24, 25 and 30 
Symptoms: questions 6, 9 and 16-22 
Miscellaneous: questions 7, 8, 10, 28 and 29 
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Legend to figures 
Fig. 1: body weight (Kg), BMI (kg/m
2
) and waist circumference (cm) (expressed as median, upper and lower limits) 
during hydrocortisone (HC) regimen, and after 1 (1M), 3 (3M), 6 (6M) and 12 months (12M) of Plenadren (PLEN), in 
patients with Addison’s disease. * P<0.05 vs. HC 
Fig. 2: fasting glucose (mg/dl) and HbA1c (mmol/mol) (expressed as median, upper and lower limits) during 
hydrocortisone (HC) regimen, and after 1 (1M), 3 (3M), 6 (6M) and 12 months (12M) of Plenadren (PLEN), in 
patients with Addison’s disease. * P<0.05 vs. HC 
Fig. 3: Total cholesterol (TC), triglycerides (TG), HDL-cholesterol and LDL-cholesterol (mg/dl; expressed as median, 
upper and lower limits) during hydrocortisone (HC) regimen, and after 1 (1M), 3 (3M), 6 (6M) and 12 months (12M) 
of Plenadren (PLEN), in patients with Addison’s disease. * P<0.05 vs. HC 
Fig. 4: ACTH (pg/ml) and cortisol (µg/dl) levels and AUCs (expressed as median, upper and lower limits) during 
hydrocortisone (HC) regimen, and after 1 (1M) and 12 months (12M) of Plenadren (PLEN), in patients with Addison’s 
disease. * P<0.05 vs. HC 
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